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Objectives We sought to examine the prognostic value of subclinical left ventricular (LV) regional myocardial dysfunction
(RMD) measured by magnetic resonance imaging (MRI) among asymptomatic individuals.
Background LV RMD, defined as segmental impairment in systolic wall thickening, predicts adverse events in patients with
established cardiovascular disease. MRI is highly accurate for detecting subtle RMD, of which the prognostic sig-
nificance in a large multiethnic asymptomatic population is not known.
Methods We used MRI to evaluate baseline regional LV myocardial function and prospectively followed a multiethnic (Afri-
can American, Caucasian, Chinese, and Hispanic) population-based sample of 4,510 men and women without
cardiovascular disease for a mean of 4.6 years. Regional myocardial dysfunction was defined as the presence of
impaired systolic wall thickening (10th percentile of segment-specific population distribution) in 2 contigu-
ous LV segments within any given coronary artery territory.
Results Baseline prevalence of RMD was 25.6%. Heart failure developed in 34 (1.0%) and 30 (2.6%) participants with-
out and with RMD, respectively (p  0.001). After adjustment for demographics and traditional risk factors,
RMD remained independently associated with incident heart failure (hazard ratio [HR]: 2.62; 95% confidence
interval [CI]: 1.56 to 4.39; p  0.001). The relationship persisted after further adjustment for biomarkers of re-
ported association with cardiovascular disease and indexes of global LV systolic dysfunction and hypertrophy
(HR: 1.80; 95% CI: 1.02 to 3.20; p  0.044). Similarly, RMD independently conferred an increased risk for hard
coronary events (myocardial infarction or death from coronary heart disease; HR: 1.75; 95% CI: 1.06 to 2.89;
p  0.029), the composite of hard coronary events and stroke (HR: 1.72; 95% CI: 1.16 to 2.56; p  0.005), and
all atherosclerotic cardiovascular events (HR: 1.50; 95% CI: 1.09 to 2.07; p  0.012).
Conclusions Among an asymptomatic multiethnic American cohort, RMD is an independent predictor beyond traditional risk
factors and global LV assessment for incident heart failure and atherosclerotic cardiovascular events. The clini-
cal utility of early recognition of this subclinical phenotype deserves further investigation. (Multi-Ethnic Study of
Atherosclerosis [MESA]; NCT00005487) (J Am Coll Cardiol 2011;57:1735–44) © 2011 by the American Col-
lege of Cardiology Foundation
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Prognosis of Regional Myocardial Dysfunction April 26, 2011:1735–44Epidemiologic studies have re-
ported that left ventricular (LV)
hypertrophy and depressed ejec-
tion fraction predict develop-
ment of heart failure in asymp-
tomatic individuals (1–4). These
global alterations in LV structure
and function have since been rec-
ognized as important subclinical
therapeutic targets in the effort to
delay progression to symptom-
atic heart failure (5,6). However,
the unfavorable progressive na-
ture of heart failure underscores
the importance of better defining
its earlier subclinical manifesta-
tions. Because coronary artery
disease is the major cause of LV
dysfunction (7,8), it is conceiv-
able that as with coronary atherosclerosis, incipient myocar-
dial dysfunction would commence as a regional process
antedating global LV dysfunction.
The assessment of systolic wall thickening (SWT) is a
validated technique for evaluating regional LV myocardial
function (9). Magnetic resonance imaging (MRI) is the
reference standard for assessing regional LV structure and
function (10,11). In this study, we used the data collected
from the MESA (Multi-Ethnic Study of Atherosclerosis)
cohort to evaluate the relationship between subclinical
regional myocardial dysfunction (RMD), detected by MRI
as reduced SWT, and incident cardiovascular events in a
large, multiethnic, asymptomatic population without base-
line clinical cardiovascular disease.
Methods
Study design and participants. MESA was a multicenter,
prospective cohort study designed to examine the preva-
lence, correlates, and progression of subclinical cardiovas-
cular disease. Details of its rationale and methodology have
been published (12). Briefly, the MESA cohort comprised
6,814 men and women and was a population-based sample
from 6 communities (Baltimore County, Maryland; Chi-
cago, Illinois; Forsyth County, North Carolina; Los Ange-
les County, California; Northern Manhattan and the Bronx,
New York; and St. Paul, Minnesota) recruited between
2000 and 2002. Eligible participants were between 45 and
84 years of age from 4 self-identified ethnicities (African
American, Caucasian, Chinese, and Hispanic) without
known clinical cardiovascular disease at enrollment. The
study was approved by the institutional review board of each
center, and all participants provided written informed
consent.
Cardiac MRI. Consenting eligible participants underwent
cardiac MRI at enrollment. The complete MRI protocol
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
LAD  left anterior
descending artery
LCx  left circumflex
artery
LV  left ventricle
MRI  magnetic resonance
imaging
RCA  right coronary
artery
RMD  regional myocardial
dysfunction
SWT  systolic wall
thickeningwas detailed elsewhere (13,14). Briefly, MRI was performed rusing commercially available 1.5-T scanners. After acquisi-
tion of scout images, 2- and 4-chamber cine images were
obtained. Short-axis cine images covering the entire LV
were then acquired from above the mitral valve plane to LV
apex using segmented k-space, electrocardiogram (ECG)-
triggered flow-compensated fast gradient echo sequence
(time to repetition/echo time: 8 to 10 ms/3 to 5 ms, flip
angle: 20o, slice thickness/gap: 6 mm/4 mm, in-plane
esolution: 1.4 to 1.6 mm  2.2 to 2.5 mm, temporal
esolution: 46  8 ms).
Using Q-MASS software (version 4.2, Medis, the Neth-
rlands), the endocardial and epicardial borders of the LV
ere traced semiautomatically at end-systole and end-
iastole on short-axis cine images. Regional wall thickness
as determined by Q-MASS, which uses the validated
odified centerline method incorporating a 3-dimensional
nalytic approach (15). Systolic wall thickening was calcu-
ated as the percentage change in wall thickness from
nd-diastole to end-systole: SWT (in %)  (ESWT –
DWT)/EDWT  100%, where ESWT indicates end-
ystolic wall thickness and EDWT indicates end-diastolic
all thickness, and was measured separately for 6 equally
artitioned segments on each of the 3 short-axis planes
apex, mid-cavity, and base) of the LV. The 6 apical
egments as partitioned and quantified were condensed into
segments by combining, respectively, the 2 adjacent septal
nd lateral wall segments for consistency with published
egmentation definition (16). Because there were segmental
ariations in SWT measured by MRI among MESA
articipants without traditional risk factors, abnormal values
f SWT on MRI were expected to be segment specific.
ccordingly, abnormal SWT in a specific segment was
efined a priori as below the 10th percentile of its segment-
pecific distribution among a healthy reference MESA
opulation without obesity, hypertension, or diabetes (n 
,778; age 59  10 years; female 49.9%; African American
6.3%, Caucasian 45.9%, Chinese 17.0%, Hispanic 20.8%).
V RMD was defined as the presence of abnormal SWT in
2 contiguous segments within the same coronary arterial
erritory. The assignment of LV segments to coronary
erritories (left anterior descending [LAD], left circumflex
LCx], and right coronary artery [RCA]) followed pub-
ished recommendations (16). The means  SD of the
egment-specific abnormal segmental SWT threshold of the
AD, RCA, and LCx segments were 22  9%, 24  14%,
nd 28 10%, respectively. A participant was considered as
aving RMD if it was present in at least 1 coronary territory.
etails on image analysis, data quality control, calculations
or LV ejection fraction and mass, and reproducibility of
hese global LV measurements have been published (14).
or regional LV myocardial function in accordance with the
6-segment model (16), reliability for single segmental
easurement of SWT (intraobserver and interobserver in-
raclass correlation coefficients of 0.73, 95% confidence
nterval [CI]: 0.69 to 0.76; and 0.68, 95% CI: 0.63 to 0.72,
espectively) and its overall variability (intraobserver and
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April 26, 2011:1735–44 Prognosis of Regional Myocardial Dysfunctioninterobserver differences of 0.3  15.3% and 0.9 
17.3%, respectively) were determined among the same
random subset of 75 MESA participants as previously
reported (14).
Risk factors and clinical covariates. At baseline, desig-
nated research personnel collected clinical information on
cardiovascular risk factors, including family history of cor-
onary artery disease, smoking status (never, former, or
current) and amount (pack-years), hypertension, diabetes,
medication use, and physical activity using the standard
semiquantitative MESA Typical Week Physical Activity
Survey for derivation of intentional exercise and moderate/
vigorous physical activity measures (metabolic equivalent
min/week) (17). Physical examination, including measure-
ments of seated brachial blood pressure, resting pulse rate,
and anthropometric indexes, was conducted in accordance
with a standardized protocol. Hypertension was defined by
the recommendations of the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation
and Treatment of High Blood Pressure (18). Diabetes was
diagnosed per the American Diabetes Association criteria or
use of antihyperglycemic therapy. Laboratory measurements
of 12-h fasting glucose and lipoprotein cholesterol concen-
trations, serum creatinine, and novel biomarkers were col-
lected and analyzed at a central core laboratory.
Follow-up and definition of clinical events. In addition
to 6 follow-up MESA examinations, participants were
followed at intervals of every 9 to 12 months for interim
cardiovascular events via telephone interviews, which were
complete in 92% of living participants. Next-of-kin inter-
views were conducted for participants with out-of-hospital
cardiovascular deaths. Medical records of 98% and 95% of
all self-reported incident cardiovascular events associated
with hospitalizations and outpatient cardiovascular diagnos-
tic encounters, respectively, were reviewed. Two physicians
of the MESA mortality and morbidity committee blinded
to cardiac MRI findings independently classified events and
assigned incidence dates. Disagreement was resolved
through adjudication by the full committee.
In this study, the primary outcome measure was incident
symptomatic heart failure, which was pre-defined in MESA
and required documentation of symptoms and/or signs, as
well as physician diagnosis and treatment, with or without
additional objective evidence of pulmonary edema/
congestion by chest radiograph and/or LV dysfunction by
clinical imaging. Ejection fraction by clinical imaging at
index event, if available, was used in this investigation for
descriptive subclassification into systolic (ejection fraction
50%) or diastolic (ejection fraction 50% or qualitatively
normal) heart failure. Moreover, we studied 4 secondary
outcome measures defined a priori in MESA, based on
pre-specified clinical event definitions: 1) myocardial infarc-
tion, resuscitated cardiac arrest, and death from coronary
disease were classified as hard coronary events; 2) composite
of all coronary events additionally included definite angina
and probable angina followed by revascularization; 3) hard vcardiovascular events encompassed hard coronary events
plus fatal and nonfatal stroke; and 4) the composite end-
point of all cardiovascular events was defined by deaths
related to atherosclerotic diseases and any of the coronary
and hard cardiovascular events. A detailed description of the
methodology for follow-up, definitions of the individual
clinical endpoints, and adjudication of clinical events is
available (19,20).
Statistical analysis. Continuous variables with normal dis-
tribution are presented as mean  SD and were compared
by 1-way analysis of variance. All non-normally distributed
variables were found to exhibit skewed distribution and are
reported as median (interquartile range), with comparisons
conducted by Mann-Whitney test. Discrete variables are
described as counts and percentages with differences exam-
ined by chi-square tests. Differences in baseline character-
istics between subgroups with and without RMD were first
examined. To contrast intergroup differences in incidence of
clinical events since enrollment, Kaplan-Meier cumulative-
event curves were constructed and compared using the
log-rank test. The unadjusted hazard ratio (HR) for each
clinical endpoint with individuals, having no RMD as the
reference group, was reported. The independent association
between RMD and incident clinical events was examined
using Cox proportional hazards models with forced entry of
the presence of RMD as a dichotomous predictor variable
and adjustment for covariates in a hierarchic manner (mod-
els 1 to 4). Continuous variable covariates with skewed
distributions were logarithmically transformed before entry
into models. Proportionality assumptions were verified by
examining time-dependent covariates. In the base models
(model 1), adjustment was made for demographics, tradi-
tional risk factors, and physical activity. Additional models
(model 2) were constructed with further adjustment for
biomarkers of reported association with myocardial dys-
function and/or cardiovascular events in asymptomatic pop-
ulations. Finally, depressed LV ejection fraction and in-
creased LV mass index (LV mass [g] normalized to body
surface area [m2]) as respective indicators of global LV
ystolic dysfunction and LV hypertrophy were entered into
set of more fully adjusted models (models 3 and 4).
ecause myocardial infarction is a well-recognized cause of
eart failure, myocardial infarction during follow-up (in-
erim myocardial infarction) was additionally included and
odeled as a time-dependent covariate in each hierarchic
odel for heart failure. Furthermore, we performed explor-
tory analyses to examine the prognostic significance of
MD among participants with confirmed normal baseline
V ejection fraction (50%) only—a conceivably lower-risk
ubgroup without contemporary regard of harboring sub-
linical global LV systolic dysfunction. First, we restricted
ur comparative analyses to within this selected subgroup.
econd, we tested for interactions between RMD and
jection fraction to evaluate any heterogeneity in the prog-
ostic significance of RMD across subgroups with normal
ersus abnormal ejection fraction. All analyses were per-
h
e
F
I
T
e
d
i
p
9
e
t
t
fi
r
d
h
w
1
I
a
t
c
i
t
c
t
a
a
1
s
R
a
t
R
e
(
(
9
b
C
e
t
2
1
f
a
t
w
g
e
a
D
T
s
M
v
q
1738 Yan et al. JACC Vol. 57, No. 17, 2011
Prognosis of Regional Myocardial Dysfunction April 26, 2011:1735–44formed using SPSS version 16.0 (SPSS Inc., Chicago, Illinois)
and Stata version 10.0 (StataCorp, College Station, Texas).
Statistical significance was inferred at 2-sided p  0.05.
Results
Clinical characteristics of study cohort. Among the 6,814
participants of the MESA cohort, 5,004 (73%) had a
baseline cardiac MRI examination. Technically adequate
data for complete quantitative measurements of regional
SWT of all LV segments was available for 4,514 partici-
pants; of these participants, 4,510 (66% of the total cohort)
had complete follow-up information and constituted the
study population. Of the 4,510 study participants, the
prevalence of RMD in the LAD, LCx, and RCA territories
was 13.2%, 10.3%, and 11.3%, respectively. Overall, 1,154
participants (25.6%) had RMD, with 815 (18.1%), 263
(5.8%), and 76 (1.7%) of them exhibiting it in 1, 2, and all
3 coronary territories, respectively. The baseline character-
istics of the study population according to RMD status are
depicted in Table 1. Compared with participants without
RMD, those with this abnormality were less likely to be
female and had higher diastolic blood pressure and waist-
to-hip ratio, lower high-density lipoprotein cholesterol
level, higher serum creatinine and homocysteine levels,
relatively higher LV mass index and lower ejection fraction
(although both were still well within normal limits), and
lower average segmental SWT for each of the 3 coronary
territories (Table 1).
RMD, heart failure, and atherosclerotic clinical events.
Over a mean follow-up of 4.6  0.8 years, heart failure
developed in 64 participants (1.4%), and 16 of them had an
interim myocardial infarction (mean elapsed time 48 days).
Of these 64 participants with incident heart failure, 35
(54.7%) and 21 (32.8%) had systolic and diastolic heart
failure, respectively, whereas the remaining 8 (12.5%) par-
ticipants had no ejection fraction data recorded at the index
event, precluding such mechanistic distinction. There were
148 (3.3%) and 200 (4.4%) members in the study cohort
sustaining the composite endpoints of all coronary and all
cardiovascular events, respectively. The incidences of heart
failure and secondary composite endpoints of hard and all
coronary as well as cardiovascular events among subgroups
of participants without and with baseline RMD are sum-
marized in Table 2. Intergroup differences in cumulative
event rates over time are shown in Figures 1 and 2. Of note,
participants with RMD were at significantly higher risk for
incident heart failure (unadjusted HR: 2.62; 95% CI: 1.60
to 4.28; p 0.001) and at elevated risk for the composite of
ard and all coronary events as well as cardiovascular
ndpoints (unadjusted HR: 1.46 to 1.72; p  0.02) (Table 2,
igs. 1 and 2).
ndependent association between RMD and heart failure.
he independent association between RMD and clinical
vents is summarized in Table 3. After adjustment for
emographics, traditional risk factors, physical activity, and cnterim myocardial infarction (model 1), RMD was inde-
endently associated with incident heart failure (HR: 2.62;
5% CI: 1.56 to 4.39; p 0.001). Adjustment for biomark-
rs reportedly related to impaired regional myocardial func-
ion and/or incident heart failure in asymptomatic popula-
ions (serum creatinine, C-reactive protein, interleukin 6,
brinogen, and homocysteine) did not significantly alter the
elationship (model 2). After additional adjustment for
epressed LV ejection fraction (model 3) and further for LV
ypertrophy (model 4), the association with heart failure
as attenuated but remained significant (HR: 1.80; 95% CI:
.02 to 3.20; p  0.044).
ndependent association between RMD and incident
therosclerotic cardiovascular events. The occurrence of
he first hard and the composite of all coronary and
ardiovascular events was consistently more frequent in
ndividuals with baseline RMD compared with their coun-
erparts without regional dysfunction (Table 2). In hierar-
hic multivariable Cox regression analyses, RMD was found
o be a significant independent predictor of incident hard
nd the composite of all coronary and cardiovascular events,
lbeit with relatively lower HRs (HR estimates: 1.50 to
.82; p  0.05) than that in the corresponding model for
ymptomatic heart failure. Moreover, relationships between
MD at study entry and cardiovascular events persisted
fter adjustment for global LV systolic function and hyper-
rophy (Table 3).
MD despite normal ejection fraction and cardiovascular
vents. Among participants with normal LV ejection fraction
n 4,433), RMD conferred an increased risk for heart failure
n  49) beyond traditional risk factors (model 1 HR: 1.83;
5% CI: 1.00 to 3.32; p  0.049) but not after controlling for
iomarkers and global LV evaluation (model 4 HR: 1.55; 95%
I: 0.82 to 2.93; p  0.18). Moreover, for atherosclerotic
ndpoints, RMD portended significantly increased hazards for
he composite of hard (n  118; HR: 1.58; 95% CI: 1.04 to
.38; p  0.030) and all cardiovascular events (n  188; HR:
.40; 95% CI: 1.01 to 1.96; p  0.046) independent of risk
actors, biomarkers, and global LV assessment in the fully-
djusted models.
As demonstrated for the entire study cohort, the respec-
ive associations between RMD and incident heart failure as
ell as each secondary atherosclerotic endpoint were homo-
eneous across participants with normal versus abnormal
jection fraction (p for interaction-heart failure  0.13;
therosclerotic endpoints 0.45).
iscussion
his present study is the first to our knowledge to demon-
trate that subclinical RMD quantitatively measured by
RI among asymptomatic adults without known cardio-
ascular diseases is independently associated with subse-
uent development of heart failure and adverse cardiovas-
ular events. Specifically, the presence of RMD confers
ry; LDL
a
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1.75-fold increased risk for combined adverse atheroscle-
rotic events over a mean follow-up of 4.6 years among
asymptomatic adults of 4 ethnic groups, independent of
indexes of global LV assessment. These findings indicate
that RMD is an important phenotypic manifestation of
early subclinical disease and that its accurate quantitative
Clinical Characteristics of MESA Participants Without and With BaTable 1 Clinical Characteristics of MESA Participants ithout
Participants Without RM
Age, yrs† 61.5 10
Women 1,788 (53.3
Ethnicity
African American 854 (25.4)
Chinese 442 (13.2)
Hispanic 739 (22.0)
Caucasian 1,321 (39.4
Hypertension 1,413 (42.1
Systolic blood pressure, mm Hg† 126 21
Diastolic blood pressure, mm Hg† 72 10
Pulse rate, beats/min† 63 9
Body mass index, kg/m2† 27.7 4.9
Waist-to-hip ratio† 0.92 0.08
Smoking status
Never 1,726 (51.6
Former smoker 1,208 (36.1
Current smoker 412 (12.3)
Cumulative smoking, pack-yrs† 10.7 23.2
Total cholesterol, mg/dl† 194 35
LDL cholesterol, mg/dl† 117 31
HDL cholesterol, mg/dl† 52 15
Treatment for hyperlipidemia 537 (16.0)
Diabetes 382 (11.4)
Physical activity, MET-min/week‡
Intentional exercise 938 (210–2,1
Moderate and vigorous physical activity 4,200 (2,091–7
Fasting glucose, mg/dl† 96 28
Serum creatinine, mg/dl† 0.95 0.24
Microalbuminuria 247 (7.4)
Macroalbuminuria 42 (1.3)
C-reactive protein, mg/l‡ 1.77 (0.77–4.
Fibrinogen, mg/dl† 342 71
Interleukin-6, pg/ml† 1.5 1.2
Homocysteine, mol/l† 9.1 3.3
Q-wave on electrocardiogram 34 (1.0)
LV hypertrophy on electrocardiogram 32 (1.0)
LV ejection fraction, %†§ 70 6
LV mass index, g/m2†§
Women (n  2,318) 71 12
Men (n  2,192) 84 15
Regional myocardial function, SWT (%)†§
Average SWT of LAD segments 68 21
Average SWT of RCA segments 66 19
Average SWT of LCx segments 81 24
All data are presented as mean SD, n (%), or median (interquartile range). *For categoric variable
‡Intergroup comparison by Mann-Whitney test. §Determined by Q-MASS on magnetic resonance
HDL high-density lipoprotein; LAD left anterior descending artery; LCx left circumflex arte
rtery; RMD  regional myocardial dysfunction; SWT  systolic wall thickening.delineation can potentially refine risk stratification ofasymptomatic individuals for incident heart failure and
clinically overt cardiovascular diseases.
Earlier clinical and epidemiologic studies have largely
employed echocardiography and focused on indexes of
global LV structure and function to examine the transition
from subclinical to symptomatic disease (2,3). These im-
portant studies have firmly established that diffuse altera-
e RMDWith Baseline RMD
3,356) Participants With RMD (n  1,154) p Value*
61.2 10 0.34
530 (45.9) 0.001
0.005
341 (29.5)
115 (10.0)
250 (21.7)
448 (38.8)
495 (42.8) 0.68
125 22 0.15
73 11 0.001
63 10 0.12
27.8 5.0 0.79
0.93 0.08 0.026
0.13
574 (49.9)
409 (35.5)
168 (14.6)
11.4 20.0 0.34
194 36 0.74
118 32 0.26
50 15 0.004
168 (14.6) 0.24
136 (11.8) 0.73
840 (125–2,100) 0.12
4,117 (2,100–7,860) 0.92
97 31 0.29
0.99 0.43 0.001
14 (1.2) 0.98
14 (1.2) 0.98
1.80 (0.78–4.04) 0.52
345 72 0.11
1.5 1.1 0.84
9.4 3.4 0.008
15 (1.3) 0.42
17 (1.5) 0.15
65 9 0.001
73 14 0.001
89 19 0.001
48 20 0.001
47 18 0.001
59 23 0.001
ue was generated from the chi-square test. †Intergroup comparison by 1-way analysis of variance.
examination.
 low-density lipoprotein; LV left ventricular; METmetabolic equivalent; RCA right coronaryselinand
D (n 
)
)
)
)
)
00)
,665)
05)
s, p val
imagingtions of LV architecture and function manifesting as global
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Prognosis of Regional Myocardial Dysfunction April 26, 2011:1735–44LV dilation and impaired ejection fraction are largely
irreversible, and once they are present, progression to
symptomatic disease can be inexorable (2,3,21). This unfa-
vorable evolution highlights the need to characterize and
detect earlier stages of asymptomatic myocardial dysfunc-
tion upstream to the development of global ventricular
dysfunction.
The traditional paradigm linking global LV alterations
and clinical events in ischemic heart disease asserts that the
genesis and progression of myocardial dysfunction result
from repeated myocardial damage secondary to multiple
episodes of silent or clinically apparent myocardial infarc-
tion, with ensuing compensatory ventricular remodeling.
Furthermore, the infliction of myocardial damage by various
other etiologic factors leading to myocardial dysfunction
was traditionally perceived as homogeneous and global in
nature. However, emerging data from other investigators
and our myocardial tagging ancillary studies in MESA have
suggested a more heterogeneous and regional interplay
between risk factors and subclinical disease (22–24). In
Incidence and Unadjusted HRs of Adverse Clinical Outcome by theTable 2 Incidence and Unadjusted HRs of Adverse Clinical Out
Incident Clinical Events
Participants Without RMD
(n  3,356)
Heart failure 34 (1.0)
Hard coronary events* 50 (1.5)
All coronary events† 98 (2.9)
Hard cardiovascular events‡ 82 (2.4)
All cardiovascular events§ 134 (4.0)
Values are n (%) unless otherwise indicated. *Myocardial infarction, resuscitated cardiac arrest, or d
by revascularization. ‡Hard coronary events, nonfatal and fatal stroke. §All coronary events, nonf
CI  confidence interval; HR  hazard ratio; RMD  regional myocardial dysfunction.
Figure 1 Kaplan-Meier Analysis for the Primary Endpoint
of Incident Heart Failure
Kaplan-Meier curve illustrating cumulative incidence of heart failure among sub-
groups of participants without (blue) and with (green) baseline regional myo-
cardial dysfunction (log-rank test for difference p  0.001).particular, using myocardial tagging as the reference stan-
dard to evaluate regional myocardial function, we previously
demonstrated a regional relationship between coronary ar-
tery calcification and systolic circumferential strain in the
corresponding perfusion territory among MESA partici-
pants who were free of clinical cardiovascular disease (22).
Similarly, a regional relationship exists between subclinical
reduction in myocardial perfusion reserve and impaired
systolic circumferential strain among asymptomatic MESA
participants (23). These cross-sectional observations provide
supporting evidence for a regional basis underlying the
inception of myocardial dysfunction along the subclinical
disease continuum, which importantly, as demonstrated in
this prospective analysis on our larger entire MESA MRI
cohort, is associated with incident cardiovascular events.
The precise etiology underlying asymptomatic RMD is
not completely understood. It is likely multifactorial and
related in part to the cumulative exposure to various ath-
erosclerotic and nonatherosclerotic risk factors leading to
diverse intermediate disease processes including endothelial
dysfunction (25,26), progressive myocyte overload (27,28),
inflammatory (29,30) and oxidative (31) myocardial injury,
microvascular disease (32), and microembolization (33). All
of these pathophysiologic plausibilities are conceptually
regional in nature and concordant with the hypothesis that
early myocardial dysfunction may commence in a regional
manner before progression to global ventricular dysfunction.
Endeavors to elucidate the disease processes that precede
global ventricular dysfunction and its clinical implications
have been undertaken mainly in patients with ischemic
heart disease (34–36) and heart failure (37). Among these
selected symptomatic individuals, regional wall motion ab-
normalities identified by echocardiography have been shown
to predict death and heart failure hospitalization. More
recently, regional wall motion abnormalities detected visu-
ally by echocardiography among a subset of 2,864 clinically
apparent disease-free individuals enrolled in the SHS
(Strong Heart Study) have been shown to be independently
associated with adverse cardiovascular outcomes (38). Of
note, the predominantly American-Indian population of the
SHS study also exhibited elevated risk for cardiovascular
ence/Absence of RMDby the Presence/Absence of RMD
icipants With RMD
(n  1,154)
Unadjusted HR (95% CI)
(Referent: No RMD) p Value
30 (2.6) 2.62 (1.60–4.28) 0.001
29 (2.5) 1.72 (1.09–2.72) 0.020
50 (4.3) 1.51 (1.08–2.13) 0.017
44 (3.8) 1.59 (1.10–2.29) 0.013
66 (5.7) 1.46 (1.09–1.97) 0.012
m coronary artery diseases. †Hard coronary events, definite angina, and probable angina followed
fatal stroke, and other death from atherosclerotic diseases.Prescome
Part
eath fro
atal andevents secondary to high prevalence of diabetes and obesity.
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April 26, 2011:1735–44 Prognosis of Regional Myocardial DysfunctionIn contrast to the SHS cohort, MESA participants repre-
sent a larger, ethnically diverse, exclusively asymptomatic
cohort by study design and thus are a substantially lower-
risk population. Moreover, our present analysis demon-
strates that RMD, objectively quantified by MRI, can be
detected in as many as one-quarter of this even lower-risk
asymptomatic population and represents a strong indepen-
dent predictor of incident heart failure and atherosclerotic
events. Our observations lend further credence to the
prognostic importance of even more subtle yet quantifiable
RMD by MRI among apparently healthy individuals.
As a measure of overall ventricular function, LV ejection
fraction may not reflect regional depression in contractile
function, which can be offset to a variable degree by
compensating hypercontractile segments. Expectedly, par-
ticipants with RMD had slightly lower but still normal
Figure 2 Kaplan-Meier Analyses for the Secondary Atherosclero
Kaplan-Meier curves illustrating cumulative incidences by absence (blue) and pres
(log-rank for difference, p  0.019), (B) all coronary events (log-rank for difference
(D) all cardiovascular events (log-rank for difference, p  0.011).ejection fractions. It is thus anticipated, and confirmed inour primary analyses of the entire asymptomatic cohort, that
specific evaluation of regional myocardial function probes
earlier manifestations of subclinical disease and confers
incremental risk prediction beyond assessment of global LV
systolic function that may be insensitive to incipient regional
myocardial functional impairment. Our ancillary subgroup
analysis is the first to corroborate the significant indepen-
dent association between RMD and incident adverse car-
diovascular events in asymptomatic adults with accurately
measured normal LV ejection fraction. These individuals
would not have been contemporarily considered as harbor-
ing subclinical ventricular dysfunction. This reinforces the
pathophysiologic link and incremental prognostic value of
RMD as an earlier subclinical phenotype of potential
preventive and therapeutic implications.
Study strengths and limitations. MESA was the first
ardiovascular Endpoints
green) of baseline regional myocardial dysfunction for (A) hard coronary events
0.016); (C) hard cardiovascular events (log-rank for difference, p  0.012); andtic C
ence (
, p epidemiologic study to use cardiac MRI in a large cohort to
l infarc
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Prognosis of Regional Myocardial Dysfunction April 26, 2011:1735–44evaluate incident cardiovascular events. To our best knowl-
edge, this analysis of 4,510 apparently healthy individuals is
the first and largest multiethnic investigation of asymptom-
atic RMD in relation to clinical outcome. The use of cardiac
MRI, an accurate and reproducible technique for assessing
LV morphology and function, permitted objective quanti-
fication of subtle impairment in regional myocardial func-
tion among lower-risk individuals in whom the epidemio-
logic evaluation of early subclinical disease is particularly
important and its implication on risk stratification most
clinically relevant. Furthermore, our study cohort was di-
verse in ethnicity, and our results are therefore applicable to
the general population.
Conversely, our study also had important limitations.
The complete analysis of all myocardial segments was not
possible in 490 participants (9.8%) who had MRI exami-
nations. The exclusion of these participants may have
introduced unknown bias. However, they were not system-
atically different than those who entered the analysis with
respect to risk factors and clinical outcome (data not
shown). Because all MESA participants had no known
baseline cardiovascular disease, older individuals repre-
sented a particularly healthy sample of the population at
large, and our results may be subjected to survival bias.
Our low-risk cohort afforded only sufficient power to
demonstrate a comprehensively adjusted independent
association between RMD and composite cardiovascular
events but not heart failure among the very low-risk
subgroup with normal ejection fraction. Nevertheless, our
adequately powered primary analyses establishing signif-
icant RMD associations with all a priori endpoints
examined, as well as the demonstrated prognostic homo-
geneity of RMD across different levels of ejection frac-
Cox Proportional Hazards Models for Incident Cardiovascular EventTable 3 Cox Proportional Hazards Models for Incident Cardiova
Clinical Endpoint Model 1*
Heart failure 2.62 (1.56–4.39);
p  0.001
Hard coronary events (MI, resuscitated cardiac
arrest, and death from CAD)
1.76 (1.10–2.81);
p  0.018
All coronary events (hard coronary events,
definite angina, probable angina followed by
revascularization)
1.56 (1.10–2.21);
p  0.012
Hard cardiovascular events (hard coronary
events, nonfatal and fatal stroke)
1.70 (1.17–2.48);
p  0.006
All cardiovascular events (all coronary events,
nonfatal and fatal stroke, death from other
atherosclerotic diseases)
1.55 (1.15–2.10);
p  0.004
*Model 1: adjustment for age, sex, ethnicity, hypertension/antihypertensive medications, systoli
(intentional exercise), diabetes/antihyperglycemic treatment, total cholesterol, HDL, use of lipid-m
modeled as a time-dependent covariate. †Model 2: adjustment for covariates in model 1 and biom
populations (fasting glucose, serum creatinine, C-reactive protein, fibrinogen, interleukin 6, and hom
fraction 61%, 10th percentile of reference MESA population). §Model 4: adjustment for covar
population).
CAD  coronary artery disease; MESA  Multi-Ethnic Study of Atherosclerosis; MI  myocardiation, are sufficient to have explicitly tested and robustlyconfirmed our hypothesis that RMD independently con-
fers adverse prognosis beyond ejection fraction among
apparently asymptomatic low-risk individuals.
LV ejection fraction measurements were not available in
a minority of cases of incident heart failure. On the other
hand, regardless of this limitation, the low overall incidence
of heart failure would have precluded detailed examination
of such etiologic distinction. It is also important to note that
although RMD portends a statistically significant increased
risk for incident cardiovascular events, the absolute event
rates were still low (2%/year) among individuals harboring
this subclinical abnormality. The therapeutic implications of
early detection of this subclinical disease phenotype among
otherwise low-risk individuals remain to be determined.
Therefore, our present findings should not be construed as
support for routine screening of RMD to refine cardiovas-
cular risk stratification. Nevertheless, our results afford novel
pathogenetic insights into the initiation of disease processes
and identification of potential subclinical therapeutic targets
to halt early disease progression. Although the precise
mechanisms underlying RMD and its relationship to the
development of global ventricular dysfunction are not elu-
cidated in this present analysis, longitudinal investigation of
potential pathophysiologic mechanisms remain underway in
MESA and other prospective studies. At the time of
baseline imaging data collection, MRI cine images were
obtained using fast gradient–echo pulse sequence, which
has been superseded by the newer-generation, steady-state
free precession pulse sequence capable of providing higher
signal-to-noise ratio and temporal resolution. Nevertheless,
because RMD was defined with reference to a normal
population distribution using the same MRI technique, our
findings are robust and generalizable to other accurate and
a Function of RMDr Events as a Function of RMD
RMD Adjusted HR (95% CI)
Model 2† Model 3‡ Model 4§
2.52 (1.49–4.26);
p  0.001
1.87 (1.06–3.30);
p  0.030
1.80 (1.02–3.20);
p  0.044
1.76 (1.09–2.85);
p  0.021
1.82 (1.10–2.99);
p  0.019
1.75 (1.06–2.89);
p  0.029
1.56 (1.09–2.22);
p  0.014
1.55 (1.07–2.24);
p  0.020
1.52 (1.05–2.21);
p  0.026
1.69 (1.16–2.48);
p  0.007
1.78 (1.20–2.64);
p  0.004
1.72 (1.16–2.56);
p  0.005
1.54 (1.14–2.10);
p  0.005
1.54 (1.12–2.11);
p  0.008
1.50 (1.09–2.07);
p  0.012
iastolic blood pressure, pulse rate, smoking status and amount in pack-years, physical activity
g medications, and waist-to-hip ratio. For heart failure, interim MI was additionally included and
f reported association with myocardial dysfunction and/or cardiovascular events in asymptomatic
ine). ‡Model 3: adjustment for covariates in model 2 and global LV systolic dysfunction (LV ejection
model 3 and LV hypertrophy (LV mass index 90th sex-specific percentile of reference MESA
tion; other abbreviations as in Tables 1 and 2.s asscula
c and d
odifyin
arkers o
ocyste
iates insensitive imaging modalities.
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April 26, 2011:1735–44 Prognosis of Regional Myocardial DysfunctionConclusions
Among an asymptomatic multiethnic American cohort,
RMD was independently predictive of incident heart failure
and atherosclerotic cardiovascular events beyond traditional
risk factors and global LV assessment. Therefore, RMD
may be a useful marker of subclinical disease. The clinical
utility of early recognition of RMD to refine risk stratifica-
tion and to optimize primary disease prevention warrants
further investigation.
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